Pavithra Jaivant, Author at PrimeInvestor

LIC Arogya Rakshak – should you go for it?

The LIC Arogya Rakshak falls somewhere in between a hospital daily-cash policy and a critical illness cover. It is an individual health insurance plan from a life insurer that provides a definite benefit unlike indemnity health covers that only reimburse hospital expenses. It can be taken either on an individual or a family floater basis, with one member being the Principal Insured (PI).

Pavithra Jaivant August 19, 2021 10 Comments

Sugar industry: Will ethanol blending prove a turning point?

Sugar industry: Will ethanol blending prove a turning point? Commodity prices have been rallying globally in the last few weeks, with some folks speculating if this is the start of a new commodity ‘super-cycle’. With all eyes on commodity stocks, the sweetest of them all, sugar companies, too have been trending higher. Leading players such as Balrampur Chini Mills Limited, Dhampur Sugar Mills Limited and EID Parry saw their stocks hit 52-week highs in June (Balrampur Chini Mills Limited and Dhampur Sugar Mills Limited even hit all-time highs) and some stock prices even doubled in the last six months. Here we take a look at the sugar sector in India and its nuances.

Pavithra Jaivant June 27, 2021 11 Comments

RITES, rites ltd., stock review, rites ltd review

Stock Review: RITES – A quality play on railway transport

RITES Limited, is a public sector undertaking (PSU) specializing in consultancy work in the fields of transport, infrastructure and related technologies. Established under the aegis of Indian Railways, this Miniratna (Category I) Schedule A PSU, was established in 1974 and was listed in the stock exchanges in July 2018. The Ministry of Railways owns 72.02% of the shares in RITES Limited. Starting out as an infrastructure consultant, the company evolved itself to offer both consulting and turnkey execution of engineering projects, leasing services and exports for the Indian Railways.

Pavithra Jaivant June 24, 2021 3 Comments

Stocks

Stock review: A healthy player in the diagnostics space

Growth estimates are being placed at a CAGR of around 10% for the next five years for the diagnostics sector, presenting a very attractive opportunity to players that are ready and able to take advantage. Dr Lal Path Labs is a leading diagnostics player, building up its presence outside its traditional stronghold of Delhi.

Pavithra Jaivant May 9, 2021 4 Comments

PrimeInvestor - Articles and Reports

LIC Arogya Rakshak – should you go for it?

Sugar industry: Will ethanol blending prove a turning point?

Stock Review: RITES – A quality play on railway transport

Stock review: A healthy player in the diagnostics space

Become a PrimeInvestor!